World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
37904
World Ranking
8885
National Ranking
270

Overview

Carle Paul is affiliated with the Federal University of Toulouse Midi-Pyrénées in France. Their research primarily focuses on medicine, with significant contributions to immunology and microbiology. Within these broader fields, they have specialized expertise in immunology, dermatology, immunology and allergy, rheumatology, and physiology.

The main topics addressed in their work include dermatology and skin diseases, psoriasis treatment and pathogenesis, allergic rhinitis and sensitization, urticaria and related conditions, autoimmune bullous skin diseases, health systems and economic evaluations concerning quality of life, as well as asthma and respiratory diseases.

Carle Paul has published frequently in the following venues:

  • Journal of the European Academy of Dermatology and Venereology
  • Annales de Dermatologie et de Vénéréologie - FMC
  • Journal of the American Academy of Dermatology
  • British Journal of Dermatology
  • SKIN The Journal of Cutaneous Medicine

Their recent scholarly articles include:

  • ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children, 2020, Journal of the European Academy of Dermatology and Venereology
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis, 2021, New England Journal of Medicine
  • Bimekizumab versus Secukinumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis, 2020, New England Journal of Medicine
  • Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials, 2023, The Lancet

Carle Paul regularly collaborates with a number of researchers, frequently co-authoring publications with M.-A. Richard, C. Bulaï Livideanu, M. Tauber, D. Jullien, and P. Joly.

Best Publications

  • Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer

    E. E. Calle;C. W. Heath;R. J. Coates;J. M. Liff

  • Breast cancer and hormonal contraceptives : collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies

    E. E. Calle;C. W. Heath;H. L. Miracle-McMahill;R. J. Coates

  • Alcohol, tobacco and breast cancer - Collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease

    N Hamajima;K Hirose;K Tajima;T Rohan

  • Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

    N. Hamajima;K. Hirose;K. Tajima;T. Rohan

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.

    Pascal Joly;Maud Maho-Vaillant;Catherine Prost-Squarcioni;Vivien Hebert

  • Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence

    N. Hamajima;K. Hirose;K. Tajima;T. Rohan

  • Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Mark G. Lebwohl;Hervé Bachelez;Jonathan Barker;Giampiero Girolomoni

  • Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children

    Ulrich Wahn;Jan D. Bos;Mark Goodfield;Ruggero Caputo

  • Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

    C Paul;J Cather;M Gooderham;Y Poulin

  • European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC

    A Nast;P Gisondi;A D Ormerod;P Saiag

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

    Carle F. Paul;Vincent C. Ho;Claire McGeown;Enno Christophers

  • Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug

    Alexander Kapp;Kim Papp;Ann Bingham;Regina Fölster-Holst

  • Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.

    C. Horreau;C. Pouplard;E. Brenaut;T. Barnetche

  • Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis

    C. Paul;P. Wolkenstein;H. Adle;J. Wechsler

  • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

    Phoebe Rich;B. Sigurgeirsson;D. Thaci;J. P. Ortonne

  • Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

    E. Archier;S. Devaux;E. Castela;A. Gallini

  • Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis

    Felix M Arellano;Charles E Wentworth;Alejandro Arana;Carlos Fernández

Frequent Co-Authors

Pascal Joly
Pascal Joly University of Rouen
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kim Papp
Kim Papp Probity Medical Research
Olivier Hermine
Olivier Hermine Necker-Enfants Malades Hospital
Giampiero Girolomoni
Giampiero Girolomoni University of Verona
Kristian Reich
Kristian Reich University of Göttingen
Guy Serre
Guy Serre Federal University of Toulouse Midi-Pyrénées
Olivier Chosidow
Olivier Chosidow Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering alternative or complementary career paths to a traditional MD, online nursing programs offer accessible and flexible options. There is a wide range of online nursing courses that make it easier for aspiring healthcare professionals to start or advance in their careers from anywhere.

For registered nurses seeking career growth, cheap rn to bsn online programs are a popular choice. These affordable pathway programs allow nurses to earn a bachelor’s degree while continuing to work, making advancement accessible and cost-effective.

Individuals with a non-nursing bachelor’s degree can pursue leadership roles in healthcare through non nursing bachelor's to msn online programs. These direct-entry options are designed for career changers who want to quickly transition into advanced nursing positions.

For those committed to research or academia, online nursing phd programs provide a pathway to the highest qualifications in nursing. These flexible doctoral programs support working professionals who aim to specialize in leadership or research within healthcare.

Best Scientists Citing Carle Paul

Trending Scientists